A new host for the manufacture of challenging drug targets

随着对癌症、疟疾和寄生虫病等主题的研究取得进展并扩展到药物发现和治疗方案，获得确保取得成功成果所需的工具变得越来越重要。治疗学发展的一个限制因素是缺乏用于候选药物活性测定或机制/结构研究的重组蛋白。仅供研究使用（RUO）的蛋白质是关键试剂，但可用性往往不可靠，现有的生产方法要么根本无法产生分子，要么价格极高。BCL的新型梭状菌表达系统具有表达以前在任何现有表达系统中无法获得的蛋白质的能力。该项目旨在开发和优化该系统，以提高产量，并解决一些在田间最难表达的蛋白质。

As research into topics such as cancer, malaria and parasitic diseases advances and expands into drug discovery and treatment programmes, access to the tools needed to ensure successful outcomes become increasingly important. A limiting factor in the development of therapeutics is a lack of recombinant proteins for candidate drug activity assays or for mechanistic/structural studies. Research Use Only (RUO) proteins are key reagents, yet availability is often unreliable, with existing production methods either unable to generate the molecules at all, or at extremely high prices.BCL's novel Clostridial expression system has the ability to express proteins previously unobtainable in any existing expression system. This project seeks to develop and optimise this system to increase yields and tackle some of the hardest to express proteins in the field.